Role of C-X-C chemokines as regulators of angiogenesis in lung cancer - PubMed (original) (raw)
Review
Role of C-X-C chemokines as regulators of angiogenesis in lung cancer
R M Strieter et al. J Leukoc Biol. 1995 May.
Free article
Abstract
Lung cancer is the leading cause of malignancy-related mortality in the U.S. and is predicted to increase over the remainder of this decade. Despite attempts to advance early diagnosis and use combination therapies, the clinical response of this cancer yields an overall 5-year survival rate of less than 15%. Clearly, new strategies for therapy are indicated. Although carcinogenesis is complex, tumor growth beyond 1-2 mm3 is dependent on angiogenesis. One of the potential mechanisms that allows for tumorigenesis is dysregulation of the balance of angiogenic and angiostatic factors that favors net neovascularization within the primary tumor. Numerous studies have investigated the role of a variety of molecules in the regulation of angiogenesis. Recently, interleukin-8 (IL-8), a member of the C-X-C chemokine family, has been found to be an angiogenic factor. In contrast, platelet factor 4 (PF4), another C-X-C chemokine, has been shown to have angiostatic properties. It is interesting that the major structural difference between IL-8 and PF4 is the presence of the NH2-terminal ELR (Glu-Leu-Arg) motif that precedes the first cysteine amino acid residue of IL-8 and is important in ligand/receptor interactions. We hypothesize that angiogenesis associated with tumorigenesis is dependent on members of the C-X-C chemokine family acting as either angiogenic or angiostatic factors. This paradigm predicts that the biological balance in the expression of these C-X-C chemokines dictates whether the neoplasm grows and develops metastatic potential or regresses. In this review we discuss our recent laboratory findings that support this contention and suggest that further elucidation of the biology of C-X-C chemokines in the context of neovascularization of nonsmall cell lung cancer will permit novel targeted therapy aimed specifically at attenuating tumor growth and metastasis.
Similar articles
- The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis.
Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, Iannettoni MD, Strieter RM. Addison CL, et al. Hum Gene Ther. 2000 Jan 20;11(2):247-61. doi: 10.1089/10430340050015996. Hum Gene Ther. 2000. PMID: 10680839 - CXC chemokines in angiogenesis.
Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM. Belperio JA, et al. J Leukoc Biol. 2000 Jul;68(1):1-8. J Leukoc Biol. 2000. PMID: 10914483 Review. - The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer.
Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R, Strieter RM. Arenberg DA, et al. J Leukoc Biol. 1997 Nov;62(5):554-62. doi: 10.1002/jlb.62.5.554. J Leukoc Biol. 1997. PMID: 9365108 Review. - Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer.
Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM. Keane MP, et al. J Immunol. 2004 Mar 1;172(5):2853-60. doi: 10.4049/jimmunol.172.5.2853. J Immunol. 2004. PMID: 14978086 - Improved survival in tumor-bearing SCID mice treated with interferon-gamma-inducible protein 10 (IP-10/CXCL10).
Arenberg DA, White ES, Burdick MD, Strom SR, Strieter RM. Arenberg DA, et al. Cancer Immunol Immunother. 2001 Dec;50(10):533-8. doi: 10.1007/s00262-001-0231-9. Cancer Immunol Immunother. 2001. PMID: 11776375 Free PMC article.
Cited by
- Hypoxia-Induced Inflammation in In Vitro Model of Human Blood-Brain Barrier: Modulatory Effects of the Olfactory Ensheathing Cell-Conditioned Medium.
Agafonova A, Cosentino A, Musso N, Prinzi C, Russo C, Pellitteri R, Anfuso CD, Lupo G. Agafonova A, et al. Mol Neurobiol. 2024 Oct 7. doi: 10.1007/s12035-024-04517-6. Online ahead of print. Mol Neurobiol. 2024. PMID: 39370481 - Impaired angiogenesis in diabetic critical limb ischemia is mediated by a miR-130b/INHBA signaling axis.
Cheng HS, Pérez-Cremades D, Zhuang R, Jamaiyar A, Wu W, Chen J, Tzani A, Stone L, Plutzky J, Ryan TE, Goodney PP, Creager MA, Sabatine MS, Bonaca MP, Feinberg MW. Cheng HS, et al. JCI Insight. 2023 May 22;8(10):e163041. doi: 10.1172/jci.insight.163041. JCI Insight. 2023. PMID: 37097749 Free PMC article. - Could senescence phenotypes strike the balance to promote tumor dormancy?
Chiu FY, Kvadas RM, Mheidly Z, Shahbandi A, Jackson JG. Chiu FY, et al. Cancer Metastasis Rev. 2023 Mar;42(1):143-160. doi: 10.1007/s10555-023-10089-z. Epub 2023 Feb 3. Cancer Metastasis Rev. 2023. PMID: 36735097 Free PMC article. Review. - The roles of chemokines following intracerebral hemorrhage in animal models and humans.
Wang J, Bian L, Du Y, Wang D, Jiang R, Lu J, Zhao X. Wang J, et al. Front Mol Neurosci. 2023 Jan 10;15:1091498. doi: 10.3389/fnmol.2022.1091498. eCollection 2022. Front Mol Neurosci. 2023. PMID: 36704330 Free PMC article. Review. - TRAIL receptors promote constitutive and inducible IL-8 secretion in non-small cell lung carcinoma.
Favaro F, Luciano-Mateo F, Moreno-Caceres J, Hernández-Madrigal M, Both D, Montironi C, Püschel F, Nadal E, Eldering E, Muñoz-Pinedo C. Favaro F, et al. Cell Death Dis. 2022 Dec 15;13(12):1046. doi: 10.1038/s41419-022-05495-0. Cell Death Dis. 2022. PMID: 36522309 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous